Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 0.64 |
| ▸ | INSR | P06213 | 16/20 | 0.64 |
| ▸ | NPM1 | P06748 | 11/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | PLK4 | O00444 | 1/20 | 0.61 |
| ▸ | BUB1B | O60566 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | FES | P07332 | 1/20 | 0.61 |
| ▸ | LYN | P07948 | 1/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | IGF1R | P08069 | 1/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
| ▸ | MET | P08581 | 1/20 | 0.61 |
| ▸ | ROS1 | P08922 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1545736 | 0.89 | ALK (0.78) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL14110119 | 0.89 | ALK (0.74) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL12213791 | 0.87 | ALK (0.80) | ALKINSRNPM1KCNH2PLK4 | |
| SCHEMBL1545674 | 0.87 | ALK (0.80) | ALKINSRNPM1KCNH2PLK4 | |
| SCHEMBL1545672 | 0.87 | ALK (0.80) | ALKINSRNPM1KCNH2PLK4 | |
| SCHEMBL1545856 | 0.86 | ALK (0.83) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL12245505 | 0.86 | ALK (0.46) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL12213830 | 0.85 | ALK (0.81) | ALKINSRNPM1KCNH2PLK4 | |
| SCHEMBL1546031 | 0.85 | ALK (0.81) | ALKINSRNPM1KCNH2PLK4 | |
| SCHEMBL1545630 | 0.85 | ALK (0.81) | ALKINSRNPM1KCNH2PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3012249-A1 | COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2016-04-27 | — | — | EP | claimed |
| EP-2311807-B1 | Compounds and composition as protein kinase inhibitors | NOVARTIS AG (CH) | 2015-11-11 | — | — | EP | claimed |
| EP-2311807-A1 | Compounds and composition as protein kinase inhibitors | IRM LLC (BM) | 2011-04-20 | — | — | EP | claimed |
| EP-2091918-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-08-26 | — | — | EP | claimed |
| WO-2008073687-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | claimed |
| EP-3012249-A1 | COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| EP-3012249-A1 | COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| EP-2311807-B1 | Compounds and composition as protein kinase inhibitors | NOVARTIS AG (CH) | 2015-11-11 | — | — | EP | disclosed |
| EP-2311807-B1 | Compounds and composition as protein kinase inhibitors | NOVARTIS AG (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-20150105390-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-04-16 | — | — | US | disclosed |
| US-20150105390-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-04-16 | — | — | US | disclosed |
| US-20150105390-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-04-16 | — | — | US | disclosed |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| EP-2311807-A1 | Compounds and composition as protein kinase inhibitors | IRM LLC (BM) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311807-A1 | Compounds and composition as protein kinase inhibitors | IRM LLC (BM) | 2011-04-20 | — | — | EP | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| WO-2008073687-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | ALK 23/4885INSR 67/4885NPM1 2242/4885 |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | ALK 23/4885INSR 67/4885NPM1 2242/4885 |
| US-20150105390-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | ALK 23/4885INSR 67/4885NPM1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.